GEN Exclusives

More »

GEN Poll

More »
Jan 11, 2012

Prometheus v. Mayo

During oral arguments before the U.S. Supreme Court in a case being watched closely by molecular diagnostics companies, justices repeatedly asked lawyers for Prometheus Laboratories and Mayo Collaborative Services for direction on the key question wrought by the patent litigation: When does a claim involving diagnostic and treatment-related chemical observations, among examples of natural phenomena, meet the threshold for patent eligibility?

The justices didn’t get the clear answer they sought. Now it will be up to the nine to answer the question as they decide Prometheus v. Mayo by looking to the law to determine what intellectual property molecular diagnostics companies can and cannot patent. What do you think?

What will the Supreme Court decide in this much-watched molecular diagnostic lawsuit?

In Favor of Prometheus
 
  20.0%
In Favor of Mayo
 
  70.0%
Split decision
 
  0.0%
Undecided
 
  10.0%

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »